Vericel (VCEL) Projected to Post Earnings on Thursday

Vericel (NASDAQ:VCEL - Get Free Report) is projected to post its Q1 2025 quarterly earnings results before the market opens on Thursday, May 8th. Analysts expect Vericel to post earnings of ($0.09) per share and revenue of $53.86 million for the quarter.

Vericel Trading Up 2.7 %

VCEL stock traded up $1.03 on Friday, hitting $38.95. 512,162 shares of the company's stock traded hands, compared to its average volume of 397,426. The stock has a market cap of $1.95 billion, a price-to-earnings ratio of 649.27 and a beta of 1.61. Vericel has a 1-year low of $37.39 and a 1-year high of $63.00. The stock has a fifty day moving average of $44.24 and a 200-day moving average of $51.25.

Insiders Place Their Bets

In other news, CEO Dominick Colangelo sold 24,850 shares of the stock in a transaction on Thursday, April 10th. The shares were sold at an average price of $41.89, for a total transaction of $1,040,966.50. Following the transaction, the chief executive officer now owns 260,354 shares in the company, valued at $10,906,229.06. This represents a 8.71 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Robert L. Md Zerbe sold 2,500 shares of Vericel stock in a transaction on Wednesday, February 5th. The shares were sold at an average price of $62.50, for a total transaction of $156,250.00. Following the completion of the sale, the director now directly owns 26,595 shares of the company's stock, valued at approximately $1,662,187.50. The trade was a 8.59 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 55,034 shares of company stock valued at $2,482,291 in the last three months. Insiders own 5.20% of the company's stock.

Analyst Ratings Changes

A number of equities analysts recently weighed in on the company. HC Wainwright reiterated a "buy" rating and issued a $60.00 price target on shares of Vericel in a research report on Friday, February 28th. Stephens restated an "overweight" rating and set a $65.00 price target on shares of Vericel in a report on Wednesday, January 15th. Truist Financial lowered their price objective on shares of Vericel from $61.00 to $51.00 and set a "buy" rating on the stock in a research report on Friday, April 11th. StockNews.com raised Vericel from a "sell" rating to a "hold" rating in a research report on Saturday, March 8th. Finally, Canaccord Genuity Group lifted their target price on Vericel from $64.00 to $67.00 and gave the company a "buy" rating in a research note on Monday, February 3rd. One investment analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat, Vericel has an average rating of "Moderate Buy" and an average price target of $60.86.

Vericel Company Profile

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.